Amazon Biotech Announces Agreement with New York City AIDS Clinic for AMZ 0026 Clinical Study

Strategic Insights -

Amazon Biotech, Inc., a natural plant pharmaceutical company, has come to an agreement with a New York City AIDS clinic to conduct a 40-patient double-blind study using AMZ 0026, the company's first immune modulator drug, in combination with a standard cocktail currently given to patients with AIDS. The study aims to evaluate the efficacy and safety of AMZ 0026 in treating HIV/AIDS, with the potential goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials or following the FDA Fast Track program to market.

Key Takeaways:

  • Amazon Biotech has partnered with a New York City AIDS clinic to conduct a 40-patient clinical study on AMZ 0026, a natural plant pharmaceutical drug aimed at treating HIV/AIDS.
  • The double-blind study will compare the efficacy of AMZ 0026 to a standard cocktail currently given to patients with AIDS.
  • The study is the company's first Phase I/II clinical trial for AMZ 0026, with plans to attract a joint venture partner with a major pharmaceutical company for Phase III trials.
  • The company's goal is to bring healthier pharmaceutical drugs to market by specializing in natural plant pharmaceuticals.
  • The study is expected to provide valuable insights into the safety and efficacy of AMZ 0026 in treating HIV/AIDS.
  • Amazon Biotech is a privately-held company primarily developing immune modulator drugs.

Statistics:

  • 40 patients will be enrolled in the double-blind study to evaluate the efficacy and safety of AMZ 0026.
  • The study will compare AMZ 0026 to a standard cocktail currently given to patients with AIDS.
  • The company plans to initiate Phase I/II clinical studies of AMZ 0026 in the near future.
  • Amazon Biotech aims to attract a joint venture partner with a major pharmaceutical company for Phase III trials.
  • The company hopes to follow the FDA Fast Track program to market AMZ 0026.

Sources:

  • Market Wire via COMTEX, October 25, 2005
  • Amazon Biotech, Inc., Press Release, October 25, 2005